These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

866 related articles for article (PubMed ID: 7543114)

  • 1. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults.
    Laursen T; Gravholt CH; Heickendorff L; Drustrup J; Kappelgaard AM; Jørgensen JO; Christiansen JS
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1222-8. PubMed ID: 11238512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
    Laursen T; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices.
    Jørgensen JO; Møller N; Lauritzen T; Christiansen JS
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1616-23. PubMed ID: 2189886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: I. Effects on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis.
    Johansson JO; Oscarsson J; Bjarnason R; Bengtsson BA
    Metabolism; 1996 Mar; 45(3):362-9. PubMed ID: 8606645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients.
    Laursen T; Jørgensen JO; Orskov H; Møller J; Harris AG; Christiansen JS
    Acta Endocrinol (Copenh); 1993 Nov; 129(5):399-408. PubMed ID: 7506470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites.
    Jørgensen JO; Møller N; Lauritzen T; Alberti KG; Orskov H; Christiansen JS
    J Clin Endocrinol Metab; 1990 Jan; 70(1):207-14. PubMed ID: 2294131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients.
    Jørgensen JO; Blum WF; Møller N; Ranke MB; Christiansen JS
    J Clin Endocrinol Metab; 1991 Mar; 72(3):582-7. PubMed ID: 1705258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients.
    Laursen T; Møller J; Jørgensen JO; Orskov H; Christiansen JS
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):333-9. PubMed ID: 8949572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stimulation of the 150-kilodalton insulin-like growth factor-binding protein-3 ternary complex by continuous and pulsatile patterns of growth hormone (GH) administration in GH-deficient patients.
    Laursen T; Flyvbjerg A; Jørgensen JO; Baxter RC; Christiansen JS
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4310-4. PubMed ID: 11095473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone (GH) replacement in GH-deficient adults: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections.
    Johansson JO; Wirén L; Oscarsson J; Bengtsson BA; Johannsson G
    Growth Horm IGF Res; 2003 Dec; 13(6):306-15. PubMed ID: 14624763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O; Laughlin GA; Yen SS
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factors (IGF) I and II and IGF binding proteins 1, 2 and 3 during low-dose growth hormone (GH) infusion and sequential euglycemic and hypoglycemic glucose clamps: studies in GH-deficient patients.
    Jørgensen JO; Blum WF; Horn N; Møller N; Møller J; Ranke MB; Christiansen JS
    Acta Endocrinol (Copenh); 1993 Jun; 128(6):513-20. PubMed ID: 7687807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of moderate interval exercise versus supine rest on the pharmacokinetics and pharmacodynamic profiles of subcutaneously administered growth hormone in adult growth hormone deficient patients.
    Janukonytė J; Parkner T; Lauritzen T; Christiansen JS; Frystyk J; Pedersen HS; Laursen T
    Growth Horm IGF Res; 2014 Oct; 24(5):198-204. PubMed ID: 25037883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.
    Laursen T; Grandjean B; Jørgensen JO; Christiansen JS
    Eur J Endocrinol; 1996 Sep; 135(3):309-15. PubMed ID: 8890721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levels of growth hormone, insulin-like growth factor-I (IGF-I) and -II, IGF-binding protein-1 and -3, and cortisol in prednisone-treated children with growth retardation after renal transplantation.
    Hokken-Koelega AC; Stijnen T; de Muinck Keizer-Schrama SM; Blum WF; Drop SL
    J Clin Endocrinol Metab; 1993 Oct; 77(4):932-8. PubMed ID: 7691864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of growth hormone (GH), but not insulin-like growth factor-I (IGF-I), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats.
    Gargosky SE; Tapanainen P; Rosenfeld RG
    Endocrinology; 1994 May; 134(5):2267-76. PubMed ID: 7512499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients.
    Laursen T; Møller J; Fisker S; Jorgensen JO; Christiansen JS
    Growth Horm IGF Res; 1999 Dec; 9(6):451-7. PubMed ID: 10629166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R; Bramnert M; Hägg E; Hilding A; Baylink DJ; Mohan S; Thorén M
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.
    Hilding A; Brismar K; Degerblad M; Thorén M; Hall K
    J Clin Endocrinol Metab; 1995 Sep; 80(9):2646-52. PubMed ID: 7545695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.